FGI-104

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
FGI-104
File:FGI-104 structure.png
Systematic (IUPAC) name
4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-6-[4-(hydroxymethyl)-3-methoxyphenyl]phenol
Clinical data
Legal status
  • Investigational New Drug
Identifiers
PubChem CID: 44158960
Chemical data
Formula C28H30ClN3O3
Molecular mass 492.008
  • c4cnc1cc(Cl)ccc1c4Nc(cc2CN(CC)CC)cc(c2O)-c(cc3OC)ccc3CO

FGI-104 is the name for a family of chemical compounds that act as broad-spectrum antiviral drugs, with activity against a range of viruses including Hepatitis B, Hepatitis C, HIV, Ebola virus and Venezuelan equine encephalitis virus. Compound R19 is the most preferred compound listed in the patent covering this family.[1][2][3]

Mechanism

The FGI-104 family of compounds act by inhibiting the protein TSG101, which transports newly replicated viruses to the exterior of an infected cell, and is required by many viruses to reinfect other cells. In pre-clinical studies FGI-104 has been shown to protect mice from Ebola virus disease.[1]

See also

References

  1. ↑ 1.0 1.1 http://www.ajtr.org/812004A.html Jan 2009 "FGI-104: A Broad-Spectrum Small Molecule Inhibitor of Viral Infection"
  2. ↑ Michael Kinch, Michael Goldblatt. Methods of inhibiting viral infection. Patent WO 2009/091435
  3. ↑ De Clercq E. "A Cutting-Edge View on the Current State of Antiviral Drug Development." Med Res Rev. 2013 Mar 11. doi: 10.1002/med.21281. PubMed link

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=FGI-104&oldid=824177"